Tag: prostate

1. Ipatasertib-abiraterone treatment significantly improved progression-free survival compared to placebo-abiraterone in patients with PTEN-loss metastatic castration-resistant prostate cancer. 2. Grade 3 or greater adverse events occurred in 70% of patients treated with ipatasertib plus abiraterone versus 39% in placebo plus abiraterone. Evidence Rating Level: 1 (Excellent) Study Rundown: Metastatic castration-resistant prostate cancer (mCRPC) is currently...
1. Ipatasertib-abiraterone treatment significantly improved progression-free survival compared to placebo-abiraterone in patients with PTEN-loss metastatic castration-resistant prostate cancer. 2. Grade 3 or greater adverse events occurred in 70% of patients treated with ipatasertib plus abiraterone versus 39% in placebo plus abiraterone. Evidence Rating Level: 1 (Excellent) Study Rundown: Metastatic castration-resistant prostate cancer...
1. 3-year event-free survival rates were significantly greater in the 18F-fluciclovine-PET group compared to conventional imaging. 2. Adverse reactions and toxicity levels were similar between the two groups. Evidence Rating Level: 1 (Excellent) Study Rundown: In patients with prostate cancer, prostatectomies are often followed with adjuvant or salvage radiotherapy. Postprostatectomy radiotherapy has...
1. Radiolabeled Lutetium-177 offered greater PSA response versus current standard of care, cabazitaxel. 2. Fewer grade 3-4 adverse events occurred in patients treated with Lutetium-177 compared to cabazitaxel. Evidence Rating Level: 1 (Excellent) Study Rundown: Although metastatic castration-resistant prostate cancer (mCRPC) is incurable, there exists several treatment options known to prolong overall...
1. The use of long-term transdermal estrogen for castration therapy for prostate cancer showed no difference in cardiovascular events versus current standard of care. 2. Gynecomastia was significantly more common in the transdermal estrogen group than standard of care group. Evidence Rating Level: 1 (Excellent) Study Rundown: Prostate cancer, an ongoing major...
1. Prostate cancer screening showed a continued reduction in prostate cancer incidence and mortality after a longer follow-up of 13 years compared to previous results after 9 and 11 years. 2. The absolute effect of screening was substantially increased after 13 years of follow-up, demonstrated by a reduction in the...
Classics Series, Landmark Trials in Medicine
1. Finasteride therapy was found to significantly reduce the incidence of prostate cancer compared to placebo. 2. Patients treated with finasteride were significantly more likely to have high-grade prostate cancers. 3. Patients on finasteride experienced significantly higher rates of sexual side effects, included erectile dysfunction, loss of libido, and gynecomastia Original Date...
Image: PD  1. Radical prostatectomy for early, localized prostate cancer led to better overall survival compared to watchful waiting.  2. Radical prostatectomy had greatest mortality benefit for men under 65 and those with intermediate risk tumors.  Evidence Rating Level: 1 (Excellent)  Study Rundown: Early, localized prostate cancer can be treated with radical prostatectomy...
Image: PD  1. A combination of an α-blocker (tamsulosin) and 5α reductase inhibitor (dutaseride) was shown to be superior to monotherapy for improvement in lower urinary tract symptoms for those with moderate to severe benign prostatic hyperplasia (BPH).  2. Improvement in average quality of life score was greater with combination therapy...
Image: PD Prostate Histology 1. Serial repeat prostate biopsies may raise the absolute risk of infectious morbidity for patients by up to 15%. 2. Gentamicin is linked to much higher rates of post-procedure infection than flouroquinolones. Evidence Rating: 2 (Good) Study Rundown: Active surveillance with serial ultrasound guided transrectal prostate biopsies has become...